Does Failed Mapping Predict Sentinel Lymph Node Metastasis in cN0 Breast Cancer?

References

• Andre F , IsmailaN, HenryNLet al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx. J. Clin. Oncol.37(22), 1956–1964 (2019).
   PubMed Web of Science ®Google Scholar
• Ramsey SD , BarlowWE, Gonzalez-AnguloAMet al. Integrating comparative effectiveness design elements and endpoints into a Phase III, randomized clinical trial (SWOG S1007) evaluating oncotypeDX-guided management for women with breast cancer involving lymph nodes. Contemp. Clin. Trials34(1), 1–9 (2013).
   PubMed Web of Science ®Google Scholar
• Bello DM , RussellC, McCulloughD, TiernoM, MorrowM. Lymph node status in breast cancer does not predict tumor biology [published correction appears in Ann. Surg. Oncol. 2018 Jul 19]. Ann. Surg. Oncol.25(10), 2884–2889 (2018).
   PubMed Web of Science ®Google Scholar
• Magnoni F , GalimbertiV, CorsoG, IntraM, SacchiniV, VeronesiP. Axillary surgery in breast cancer: an updated historical perspective. Semin. Oncol.47(6), 341–352 (2020).
   PubMed Web of Science ®Google Scholar
• Lyman GH , GiulianoAE, SomerfieldMRet al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J. Clin. Oncol.23(30), 7703–7720 (2015).
   Google Scholar
• Giuliano AE , HanSH. Local and regional control in breast cancer: role of sentinel node biopsy. Adv. Surg.45, 101–116 (2011).
   PubMedGoogle Scholar
• Krag DN , AndersonSJ, JulianTBet al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised Phase III trial. Lancet Oncol.8(10), 881–888 (2007).
   PubMed Web of Science ®Google Scholar
• Veronesi U , VialeG, PaganelliGet al. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann. Surg.251(4), 595–600 (2010).
   PubMed Web of Science ®Google Scholar
• Solá M , AlberroJA, FraileMet al. Complete axillary lymph node dissection versus clinical follow-up in breast cancer patients with sentinel node micrometastasis: final results from the multicenter clinical trial AATRM 048/13/2000. Ann. Surg. Oncol.20(1), 120–127 (2013).
   PubMed Web of Science ®Google Scholar
• Galimberti V , ColeBF, ZurridaSet al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a Phase 3 randomised controlled trial [published correction appears in Lancet Oncol. 2013 Jun; 14(7): e254]. Lancet Oncol.14(4), 297–305 (2013).
   PubMed Web of Science ®Google Scholar
• Galimberti V , ColeBF, VialeGet al. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled Phase 3 trial. Lancet Oncol.19(10), 1385–1393 (2018).
   PubMed Web of Science ®Google Scholar
• Sávolt á , PéleyG, PolgárCet al. Eight-year follow up result of the OTOASOR trial: the optimal treatment of the axilla - surgery or radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: a randomized, single centre, Phase III, non-inferiority trial. Eur. J. Surg. Oncol.43(4), 672–679 (2017).
   PubMed Web of Science ®Google Scholar
• Giuliano AE , BallmanK, McCallLet al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: long-term follow-up from the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial. Ann. Surg.264(3), 413–420 (2016).
   PubMed Web of Science ®Google Scholar
• Donker M , van TienhovenG, StraverMEet al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10.81–22023 AMAROS): a randomised, multicentre, open-label, Phase 3 non-inferiority trial. Lancet Oncol.15(12), 1303–1310 (2014).
   PubMed Web of Science ®Google Scholar
• Verheuvel NC , VoogdAC, Tjan-HeijnenVCG, SieslingS, RoumenRMH. Non-visualized sentinel nodes in breast cancer patients; prevalence, risk factors, and prognosis. Breast Cancer Res. Treat.167(1), 147–156 (2018).
   PubMed Web of Science ®Google Scholar
• Verheuvel NC , VoogdAC, Tjan-HeijnenVCG, RoumenRMH. What to do with non-visualized sentinel nodes? A Dutch Nationwide Survey Study. Ann. Surg. Oncol.24(8), 2155–2160 (2017).
   PubMed Web of Science ®Google Scholar
• Nowikiewicz T , Głowacka-MrotekI, TarkowskaM, NowikiewiczM, ZegarskiW. Failure of sentinel lymph node mapping in breast cancer patients qualified for treatment sparing axillary lymph nodes-clinical importance and management strategy-one-center analysis. Breast J.26(5), 873–881 (2020).
   PubMed Web of Science ®Google Scholar
• Schwartz GF , GiulianoAE, VeronesiU. Consensus Conference Committee. Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19–22, 2001, Philadelphia, Pennsylvania. Cancer94(10), 2542–2551 (2002).
   PubMed Web of Science ®Google Scholar
• NCCN Clinical practice guidelines in oncology: breast cancer (2021). www.nccn.org//profession als/physiciangls/pdf/breast.pdf
   Google Scholar
• Senkus E , KyriakidesS, OhnoSet al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol.26(Suppl. 5), v8–v30 (2015).
   PubMed Web of Science ®Google Scholar
• Murray N , WinstanleyJ, BennettA, FrancisK. Guideline Development Group. Diagnosis and treatment of advanced breast cancer: summary of NICE guidance. BMJ338, b509 (2009).
   PubMedGoogle Scholar
• Soran A , FalkJ, BonaventuraM, KeenanD, AhrendtG, JohnsonR. Does failure to visualize a sentinel node on preoperative lymphoscintigraphy predict a greater likelihood of axillary lymph node positivity?J. Am. Coll. Surg.205(1), 66–71 (2007).
   PubMed Web of Science ®Google Scholar
• Lissidini G , TrifiròG, VeronesiPet al. Could radiotherapy play a major role in misidentification of sentinel lymph node in breast cancer recurrence? Radiother. Oncol. 131, 237–238 (2019).
   PubMed Web of Science ®Google Scholar
• Veronesi U , PaganelliG, GalimbertiVet al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet349(9069), 1864–1867 (1997).
   PubMed Web of Science ®Google Scholar
• De Cicco C , ChinolM, PaganelliG. Intraoperative localization of the sentinel node in breast cancer: technical aspects of lymphoscintigraphic methods. Semin. Surg. Oncol.15(4), 268–271 (1998).
   PubMedGoogle Scholar
• De Cicco C , TrifiròG, IntraMet al. Optimised nuclear medicine method for tumour marking and sentinel node detection in occult primary breast lesions. Eur. J. Nucl. Med. Mol. Imaging31(3), 349–354 (2004).
   PubMed Web of Science ®Google Scholar
• Martin RC 2nd , EdwardsMJ, WongSLet al. Practical guidelines for optimal gamma probe detection of sentinel lymph nodes in breast cancer: results of a multi-institutional study. For the University of Louisville Breast Cancer Study Group. Surgery128(2), 139–144 (2000).
   PubMed Web of Science ®Google Scholar
• Viale G , SonzogniA, PruneriGet al. Histopathologic examination of axillary sentinel lymph nodes in breast carcinoma patients. J. Surg. Oncol.85(3), 123–128 (2004).
   PubMed Web of Science ®Google Scholar
• de Boniface J , FrisellJ, AnderssonYet al. Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial. BMC Cancer17(1), 379 (2017).
   PubMedGoogle Scholar
• Burstein HJ , CuriglianoG, LoiblSet al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann. Oncol.30(10), 1541–1557 (2019).
   PubMed Web of Science ®Google Scholar
• Giuliano AE , BallmanKV, McCallLet al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA318(10), 918–926 (2017).
   PubMed Web of Science ®Google Scholar
• Newman LA . Lymphatic mapping and sentinel lymph node biopsy in breast cancer patients: a comprehensive review of variations in performance and technique. J. Am. Coll. Surg.199(5), 804–816 (2004).
   PubMed Web of Science ®Google Scholar
• Goyal A , NewcombeRG, ManselREet al. Role of routine preoperative lymphoscintigraphy in sentinel node biopsy for breast cancer. Eur. J. Cancer41(2), 238–243 (2005).
   PubMed Web of Science ®Google Scholar
• Doting MH , JansenL, NiewegOEet al. Lymphatic mapping with intralesional tracer administration in breast carcinoma patients. Cancer88(11), 2546–2552 (2008).
   Google Scholar
• Pijpers R , MeijerS, HoekstraOSet al. Impact of lymphoscintigraphy on sentinel node identification with technetium-99m-colloidal albumin in breast cancer. J. Nucl. Med.38(3), 366–368 (1997).
   PubMed Web of Science ®Google Scholar
• Kuemmel S , HoltschmidtJ, GerberBet al. Prospective, multicenter, randomized Phase III trial evaluating the impact of lymphoscintigraphy as part of sentinel node biopsy in early breast cancer: SenSzi (GBG80) Trial. J. Clin. Oncol.37(17), 1490–1498 (2012).
   Google Scholar
• Cabanas RM . An approach for the treatment of penile carcinoma. Cancer39(2), 456–466 (1977).
   PubMed Web of Science ®Google Scholar
• Morton DL , WenDR, WongJHet al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch. Surg.127(4), 392–399 (1992).
   PubMed Web of Science ®Google Scholar
• van der Veen H , HoekstraOS, PaulMA, CuestaMA, MeijerS. Gamma probe-guided sentinel node biopsy to select patients with melanoma for lymphadenectomy. Br. J. Surg.81(12), 1769–1770 (1994).
   PubMed Web of Science ®Google Scholar
• Intra M , RotmenszN, MattarDet al. Unnecessary axillary node dissections in the sentinel lymph node era. Eur. J. Cancer43(18), 2664–2668 (2007).
   PubMed Web of Science ®Google Scholar
• Mansel RE , FallowfieldL, KissinMet al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial [published correction appears in J Natl Cancer Inst. 2006 Jun 21; 98(12): 876]. J. Natl Cancer Inst.98(9), 599–609 (2006).
   PubMedGoogle Scholar
• Kondylakis H , BucurA, DongFet al. iManage Cancer: developing a platform for Empowering patients and strengthening self-management in cancer diseases. In: 2017 IEEE 30th International Symposium on Computer-Based Medical Systems (CBMS).IEEE, 755–760 (2017).
   Google Scholar
• McMasters KM , WongSL, MartinRC2ndet al. Dermal injection of radioactive colloid is superior to peritumoral injection for breast cancer sentinel lymph node biopsy: results of a multiinstitutional study. Ann. Surg.233(5), 676–687 (2001).
   PubMed Web of Science ®Google Scholar
• Heuts EM , vander Ent FW, vander Pol HA, von MeyenfeldtMF, VoogdAC. Additional tracer injection to improve the technical success rate of lymphoscintigraphy for sentinel node biopsy in breast cancer. Ann. Surg. Oncol.16(5), 1156–1163 (2009).
   PubMed Web of Science ®Google Scholar
• Rousseau C , ClasseJM, CampionLet al. The impact of nonvisualization of sentinel nodes on lymphoscintigraphy in breast cancer. Ann. Surg. Oncol.12(7), 533–538 (2005).
   PubMed Web of Science ®Google Scholar
• Goyal A , NewcombeRG, ChhabraA, ManselRE. ALMANAC Trialists Group. Factors affecting failed localisation and false-negative rates of sentinel node biopsy in breast cancer--results of the ALMANAC validation phase. Breast Cancer Res. Treat.99(2), 203–208 (2006).
   PubMed Web of Science ®Google Scholar
• O'Reilly EA , PrichardRS, AlAzawi Det al. The value of isosulfan blue dye in addition to isotope scanning in the identification of the sentinel lymph node in breast cancer patients with a positive lymphoscintigraphy: A Randomized Controlled Trial (ISRCTN98849733). Ann. Surg.262(2), 243–248 (2015).
   PubMed Web of Science ®Google Scholar
• Johnson CB , BonetiC, KorourianS, AdkinsL, KlimbergVS. Intraoperative injection of subareolar or dermal radioisotope results in predictable identification of sentinel lymph nodes in breast cancer. Ann. Surg.254(4), 612–618 (2011).
   PubMed Web of Science ®Google Scholar
• Kang T , YiM, HuntKKet al. Does blue dye contribute to success of sentinel node mapping for breast cancer? Ann. Surg. Oncol. 17(Suppl. 03), 280–285 (2010).
   PubMedGoogle Scholar
• Straalman K , KristoffersenUS, GalatiusH, LanngC. Factors influencing sentinel lymph node identification failure in breast cancer surgery. Breast17(2), 167–171 (2008).
   PubMed Web of Science ®Google Scholar
• Kim T , GiulianoAE, LymanGH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer106(1), 4–16 (2006).
   PubMed Web of Science ®Google Scholar
• Perenyei M , BarberZE, GibsonJ, Hemington-GorseS, DobbsTD. Anaphylactic reaction rates to blue dyes used for sentinel lymph node mapping: systematic review and meta-analysis. Ann. Surg.273(6), 1087–1093 (2020).
   Web of Science ®Google Scholar
• Brenot-Rossi I , HouvenaeghelG, JacquemierJet al. Nonvisualization of axillary sentinel node during lymphoscintigraphy: is there a pathologic significance in breast cancer? J. Nucl. Med. 44(8), 1232–1237 (2003).
   PubMed Web of Science ®Google Scholar
• Birdwell RL , SmithKL, BettsBJ, IkedaDM, StraussHW, JeffreySS. Breast cancer: variables affecting sentinel lymph node visualization at preoperative lymphoscintigraphy. Radiology220(1), 47–53 (2001).
   PubMed Web of Science ®Google Scholar
• Krausz Y , IkedaDM, JadvarH, LanglebenD, BirdwellR, StraussHW. Non-visualization of sentinel lymph node in patients with breast cancer. Nucl. Med. Commun.22(1), 25–32 (2001).
   PubMed Web of Science ®Google Scholar
• Heuser T , RinkT, WellerEet al. Impact of the axillary nodal status on sentinel node mapping in breast cancer and its relevance for technical proceeding. Breast Cancer Res. Treat.67(2), 125–132 (2001).
   PubMed Web of Science ®Google Scholar
• Tanis PJ , van SandickJW, NiewegOEet al. The hidden sentinel node in breast cancer. Eur. J. Nucl. Med. Mol. Imaging29(3), 305–311 (2002).
   PubMed Web of Science ®Google Scholar
• Chakera AH , FriisE, HesseU, Al-SulimanN, ZerahnB, HesseB. Factors of importance for scintigraphic non-visualisation of sentinel nodes in breast cancer. Eur. J. Nucl. Med. Mol. Imaging32(3), 286–293 (2005).
   PubMed Web of Science ®Google Scholar
• Lo YF , HsuehS, MaSY, ChenSC, ChenMF. Clinical relevance of nonvisualized sentinel lymph nodes in unselected breast cancer patients during lymphoscintigraphy. Chang Gung Med. J.28(6), 378–386 (2005).
   PubMedGoogle Scholar
• Jansen JE , BekkerJ, de HaasMJet al. The influence of wire localisation for non-palpable breast lesions on visualisation of the sentinel node. Eur. J. Nucl. Med. Mol. Imaging33(11), 1296–1300 (2006).
   PubMed Web of Science ®Google Scholar
• Pritsivelis C , GarciaMendonça CA, PinheiroPessoa MC, Coelho-OliveiraA, GutfilenB, BarbosaDa Fonseca LM. Failure predictors of the sentinel lymph node in patients with breast cancer using Tc-99m sulfur colloid and periareolar injection. Q. J. Nucl. Med. Mol. Imaging51(2), 189–193 (2007).
   PubMed Web of Science ®Google Scholar
• Dordea M , ColvinH, CoxP, PujolNicolas A, KanakalaV, IwuchukwuO. Clinical and histopathological factors affecting failed sentinel node localization in axillary staging for breast cancer. Surgeon11(2), 63–66 (2013).
   PubMed Web of Science ®Google Scholar
• Vaz SC , SilvaÂ, SousaRet al. Breast cancer lymphoscintigraphy: factors associated with sentinel lymph node non visualization. Rev. Esp. Med. Nucl. Imagen Mol.34(6), 345–349 (2015).
   PubMed Web of Science ®Google Scholar
• Hellingman D , WanOY, deWit-van der Veen BJet al. Predictive risk factors for sentinel lymph node nonvisualization on planar lymphoscintigraphy using an intratumoral injection in patients with primary breast cancer. Nucl Med Commun.40(4), 317–324 (2019).
   PubMed Web of Science ®Google Scholar
• Chagpar A , MiddletonLP, SahinAAet al. Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry. Cancer103(8), 1581–1586 (2005).
   PubMed Web of Science ®Google Scholar
• Intra M , VialeG, VilaJet al. Second axillary sentinel lymph node biopsy for breast tumor recurrence: experience of the European Institute of Oncology. Ann. Surg. Oncol.22(7), 2372–2377 (2015).
   PubMed Web of Science ®Google Scholar
• Toesca A , LuiniA, VeronesiP, IntraM, GentiliniO. Sentinel lymph node biopsy in early breast cancer: the experience of the European Institute of Oncology in special clinical scenarios. Breast Care (Basel)6(3), 208–214 (2011).
   PubMed Web of Science ®Google Scholar
• Intra M , TrifiròG, GalimbertiV, GentiliniO, RotmenszN, VeronesiP. Second axillary sentinel node biopsy for ipsilateral breast tumour recurrence. Br. J. Surg.94(10), 1216–1219 (2007).
   PubMed Web of Science ®Google Scholar
• Intra M , VeronesiP, GentiliniODet al. Sentinel lymph node biopsy is feasible even after total mastectomy. J. Surg. Oncol.95(2), 175–179 (2007).
   PubMed Web of Science ®Google Scholar
• Rodriguez Fernandez J , MartellaS, TrifiròGet al. Sentinel node biopsy in patients with previous breast aesthetic surgery. Ann. Surg. Oncol.16(4), 989–992 (2009).
   PubMed Web of Science ®Google Scholar
• Maaskant-Braat AJ , VoogdAC, RoumenRM, NieuwenhuijzenGA. Repeat sentinel node biopsy in patients with locally recurrent breast cancer: a systematic review and meta-analysis of the literature. Breast Cancer Res. Treat.138, 13–20 (2013).
   PubMed Web of Science ®Google Scholar
• Corso G , GranaCM, GilardiLet al. Feasibility of lymphoscintigraphy for sentinel node identification after neo-adjuvant therapy. Ann. Ital. Chir.88, 201–205 (2017).
   PubMed Web of Science ®Google Scholar
• Kahler-Ribeiro-Fontana S , PaganE, MagnoniFet al. Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up. Eur. J. Surg. Oncol.47(4), 804-812 (2020).
   PubMed Web of Science ®Google Scholar
• Montagna G , MamtaniA, KnezevicA, BrogiE, BarrioAV, MorrowM. Selecting node-positive patients for axillary downstaging with neoadjuvant chemotherapy. Ann. Surg. Oncol.27(11), 4515–4522 (2020).
   PubMed Web of Science ®Google Scholar
• Tafra L , LanninDR, SwansonMSet al. Multicenter trial of sentinel node biopsy for breast cancer using both technetium sulfur colloid and isosulfan blue dye. Ann. Surg.233(1), 51–59 (2001).
   PubMed Web of Science ®Google Scholar
• National Breast and Ovarian Cancer Centre (NBOCC) Australia . Recommendations for use of sentinel node biopsy in early (operable) breast cancer (June 2008). Cancer Australia 2011 (2021). www.canceraustralia.gov.au
   Google Scholar
• Gentilini O , VeronesiU. Abandoning sentinel lymph node biopsy in early breast cancer? A new trial in progress at the European Institute of Oncology of Milan (SOUND: sentinel node vs Observation after axillary UltraSouND). Breast21(5), 678–681 (2012).
   PubMed Web of Science ®Google Scholar
• Reimer T , EngelJ, SchmidtM, OffersenBV, SmidtML, GentiliniOD. Is axillary sentinel lymph node biopsy required in patients who undergo primary breast surgery?Breast Care (Basel)13(5), 324–330 (2018).
   PubMed Web of Science ®Google Scholar